{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-009864","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.536692+00:00","generated_at":"2026-06-15T01:23:41.715328+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aprea Therapeutics Q1 net loss $4.4M; cash runway into Q3 2024; ATRN-119 Phase 1 data expected Q1 2024","bullets":["Net loss of $4.4M ($1.34 per share) on $31.0M cash; operating loss $4.6M vs $8.1M YoY.","R&D expenses $1.3M (down from $4.1M YoY) due to legacy trial closeout; G&A $3.4M.","ATRN-119 Phase 1/2a enrollment continues; initial safety, tolerability, PK data expected Q1 2024.","ATRN-1051 IND-enabling studies ongoing; IND filing anticipated by end of 2023.","Closed $4.9M net proceeds from February public offering; appointed Dr. Gabriela Gruia to board."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-009864","json":"https://secwatch.observer/filing/0001558370-23-009864.json","markdown":"https://secwatch.observer/filing/0001558370-23-009864.md","text":"https://secwatch.observer/filing/0001558370-23-009864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837023009864/0001558370-23-009864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837023009864/apre-20230515x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:23:41.715328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e9ae80b1e03195eed4fbd5d3ce642afcbd620435","claim":"Aprea Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income net loss of $4.4 million, EPS $1.34 per basic share.","evidence_excerpt":"The Company reported a net loss of $4.4 million ($1.34 per basic share) on approximately 3.3 million weighted-average common shares outstanding for the quarter ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000155837023009864/0001558370-23-009864-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"net loss of $4.4 million"},{"label":"EPS","value":"$1.34 per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}